Kevin McMahon.
​
Waltham, Mass.—SOLX, Inc., a privately held company dedicated to developing innovative surgical technologies that treat glaucoma and preserve vision, announced that Kevin McMahon has joined the company as president and chief executive officer. McMahon succeeds Doug Adams, SOLX’s founder, past president and CEO.

A veteran medical device executive, McMahon brings more than 25 years of experience to the role. Most recently, according to SOLX’ announcement, he served as president and general manager of RaySafe inc., which, under his direction, was successfully acquired by Fluke Biomedical. In his tenure, McMahon directed several successful product launches that resulted in the acquisitions of several medical technologies in the fields of ophthalmology, breast cancer and radiation oncology.

“We are delighted to welcome Kevin to SOLX,” said Eric Bednarski, partner at MVM Life Science Partners and member of the company’s board of directors. “Kevin is an exceptional leader with a proven record of success in bringing innovative new products to market. I am confident that his strong commercial and operational experience will serve SOLX well as the company moves through the regulatory process to commercialization.”

He added, “Doug is a pioneer in the field of glaucoma. We thank Doug for his entrepreneurial efforts in advancing SOLX and for his continuing support of the company.”

“The company has a strong history of advancing the development of the SOLX Gold Shunt, a novel, minimally invasive device that has the potential to improve the surgical treatment of glaucoma, especially for those patients with difficult to treat refractory glaucoma,” McMahon said. “This is an exciting time for the company as we finalize our regulatory process and move toward commercialization. There is a great, unmet need for additional treatment options for patients who struggle with glaucoma, which affects 65 million patients worldwide. I am proud to be affiliated with a company that has continued to dedicate itself to developing better solutions for glaucoma surgeons and their patients.”

The SOLX Gold Shunt is an implantable drainage device designed to reduce elevated intraocular pressure (IOP) associated with refractory glaucoma. Currently approved for use in Canada and Europe, in the U.S., the SOLX Gold Shunt is an investigational device, limited by Federal law to investigational use, the company said.

SOLX, Inc. is backed by MVM Life Science Partners, River Street Management, institutional and other investors.